Article Sidebar

PDF
Date Published: 12/04/2023
Abstract Views: 93
Views PDF: 86
DOI: https://doi.org/10.51298/vmj.v525i1A.4975
Issue
Vol. 525 No. 1A (2023)
Section
Các bài báo
How to Cite
Đỗ , H. K. ., & Nguyễn, V. T. . (2023). EVALUATING THE SURVIVAL OUTCOME AND ADVERSE EVENTS OF SECOND-LINE IRINOTECAN CHEMOTHERAPY IN EXTENSIVE SMALL CELL LUNG CANCER. Vietnam Medical Journal, 525(1A). https://doi.org/10.51298/vmj.v525i1A.4975

EVALUATING THE SURVIVAL OUTCOME AND ADVERSE EVENTS OF SECOND-LINE IRINOTECAN CHEMOTHERAPY IN EXTENSIVE SMALL CELL LUNG CANCER

Hùng Kiên Đỗ 1,, Văn Tài Nguyễn2
1 K hospital
2 k hospital

Main Article Content

Abstract

Objective: Assessing progression-free survival and adverse events of second-line irinotecan chemotherapy in patients with extensive small-cell lung cancer at the K Hospital. Patients and method: Retrospective and prospective analysis of 32 extensive small-cell lung cancer patients treated with second-line irinotecan chemotherapy at the K Hospital from January 2018 to November 2022. Results: Mean progression-free survival (PFS) was 13.9±2.3 weeks. The most common adverse events (AEs) were hematologic AEs with neutropenia grades 3-4 (18.8%) and leucopenia grades 3-4 (15.6%). Diarrhea and nausea grades 3-4 were reported in minority of patients.  Conclusion: Second-line of irinotecan chemotherapy had a good progression-free survival and the profile of toxicity was acceptable.

Article Details

Keywords

small-cell lung cancer, extensive stage, second line of irinotecan.

References

1. Foster N.R. Qi Y. Shi Q. et al. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. Cancer. 2011; 117: 1262-1271
2. Mascaux, C., Paesmans, M., Berghmans, T. et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer. 2000; 30: 23–26
3. Rossi, A., Di Maio, M., Chiodini, P. et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012; 30: 1692–1698
4. Horn L, Mansfield AS, Szczęsna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med 2018; 379:2220.
5. Goto K, Ohe Y, Shibata T, et al. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2016; 17:1147.
6. SEER Cancer Statistics Review, 1975-2016. SEER. Accessed November 26, 2022. https://seer.cancer.gov/csr/1975_2016/index.html
7. Hurwitz JL, McCoy F, Scullin P, Fennell DA. New advances in the second-line treatment of small cell lung cancer. Oncologist. 2009;14(10):986-994. doi:10.1634/theoncologist.2009-0026
8. Owonikoko TK, Behera M, Chen Z, et al. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol. 2012;7(5):866-872. doi:10.1097/JTO.0b013e31824c7f4b
9. Zhao Y, Wan B, Zhang T, et al. Irinotecan, topotecan, paclitaxel or docetaxel for second-line treatment of small cell lung cancer: a single-center retrospective study of efficiency comparation and prognosis analysis. Transl Lung Cancer Res. 2019;8(6):829-837. doi:10.21037/tlcr.2019.10.21